Abeona Therapeutics Inc. (Nasdaq: ABEO) has recently become a member of the Rare Disease Company Coalition (RDCC), a coalition consisting of life science companies that are committed to developing therapies for rare diseases. Vish Seshadri, the CEO of Abeona, has also been appointed to the RDCC's Board of Directors.
Abeona is thrilled to join forces with the RDCC and shares their dedication to advancing treatments for rare diseases. The company's main focus is on the development of EB-101, a potential therapy for patients suffering from recessive dystrophic epidermolysis bullosa—a condition characterized by severe blistering and fragile skin. Through collaboration with the RDCC, Abeona aims to advocate for policies that promote innovation and ensure patient access to life-changing treatments.
Established in 2021, the Rare Disease Company Coalition (RDCC) represents a collective effort by life science companies dedicated to discovering and delivering treatments for rare diseases. The coalition's primary objective is to educate policymakers about the unique challenges associated with drug development and manufacturing for small patient populations affected by rare diseases